CD4 and myeloid sarcoma: Compared to 13 untreated MS patients, 18 IFN-β treated patients had a significantly lower proliferative response of CD4+ T cells to the self-antigen MBP, while the proliferative response to the recall antigen TT was not significantly different in 12 untreated MS patients as compared to 18 IFN-β treated patients (Fig. 1C).